Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
January 15, 2026
In the News
Kyle Faget Assesses Regulatory Shifts Impacting Medtech
Foley & Lardner LLP partner Kyle Faget is featured in four Medtech Insight articles evaluating the medtech industry’s major developments in 2025 and examining 2026 regulatory challenges.
January 13, 2026
In the News
Louis Lehot Co-Authors 2026 M&A Technology Playbook
Foley & Lardner LLP Louis Lehot co-authored The Legal Intelligencer article, “State of Tech M&A: A 2026 Playbook for Founders Who Want to Win,” providing a practical guide for founders of emerging companies considering mergers and acquisitions.
January 13, 2026
In the News
Foley Attorneys Author Article on Uniform Assignment For Benefit of Creditors Act
Foley & Lardner LLP partner Emil Khatchatourian and associate Joseph Harper co-authored The Review of Banking & Financial Services article, “Modernizing ABCS with the Uniform Assignment For Benefit of Creditors Act."